Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Sankyo's Prasugrel Shows Reduction Of Recurrent Cardiovascular Events

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo announced August 22 that a Phase III study showed patients who took prasugrel for acute coronary syndromes were less likely to have a recurrent event than those who took competing Sanofi-Aventis drug clopidogrel. The study was conducted on patients who had a previous cardiovascular or cerebral event. Recurrent rate for prasugrel was 10.8 compared to clopidogrel's 15.4 percent. Daiichi Sankyo and Eli Lilly are jointly applying for approval. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts